Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  Amoéba    ALMIB   FR0011051598

AMOÉBA

(ALMIB)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Amoeba : Amoéba signs a non-exclusive development and marketing agreement in Switzerland with STÄHLER for its vine biocontrol product

12/18/2020 | 03:21am EST

PRESS RELEASE

AMOEBA SIGNS A NON-EXCLUSIVE DEVELOPMENT AND MARKETING

AGREEMENT IN SWITZERLAND WITH STÄHLER

FOR ITS VINE BIOCONTROL PRODUCT

Chassieu (France), December 18, 2020 - 8.30 am- AMOEBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces the signature of a Term Sheet with STÄHLER SUISSE SA, for the development and marketing of its biocontrol product against vine downy mildew in Switzerland.

This signature, with a highly recognized local player in the crop protection market, follows on from the partnership announced in March 2020 to evaluate the performance of the biocontrol fungicide containing AMOEBA's active substance: the amoeba lysate Willaertia magna C2c Maky.

The aim of the Term Sheet is to define the terms of the collaboration between the two companies before and after the marketing of the product on the Swiss territory with a view to signing a commercial partnership contract within 12 months.

Amoéba will carry out the regulatory tests necessary for the registration of its product and STÄHLER will define, through additional field trials, the marketing and commercial positioning of the product.

Amoéba has made a non-exclusive commitment with STÄHLER concerning the vine application over a marketing period of several years in Switzerland, where vine downy mildew is an important market and the search for sustainable treatment solutions a strong objective for all Swiss agriculture.

"Vine downy mildew is one of the main diseases in the Swiss vineyard. Its control today requires repeated applications of phytosanitary products. AMOEBA's biocontrol product was tested for the first time by Stähler Suisse SA in 2020 in 2 trials. The results were very encouraging and it has been decided to continue the testing and development work. The product could become an important tool for the move towards a more ecological viticulture", explains Simon Gasser, Head of Development and Certification at STÄHLER SUISSE SA.

"As the Swiss vineyard offers a wide variety of grape varieties, the choice of STÄHLER as a partner was a natural one. As a leading player in its domestic market, specialising in particular in crops such as vines, arboriculture and market gardening, the company is already heavily involved in the development and marketing of biocontrol solutions. Our common goal is to provide local winegrowers with an effective solution for vine protection without impacting the environment "comments Fabrice PLASSON, Chairman and CEO of Amoéba.

Adresse : 38 Avenue des Frères Montgolfier, 69680 CHASSIEU

Tel: +33 (0)4 26 69 16 00 - Email: contact@amoeba-nature.com

Société Anonyme au capital de 311 578,38 €

Linkedin: @amoeba-nature - Twitter: @AmoebaNature

RCS Lyon 523 877 215

www.amoeba-nature.com

About STÄHLER SUISSE SA

STÄHLER SUISSE SA is one of the leading distributors of crop protection products and biocontrol solutions in Switzerland, with a strong specialization on grapes and other valuable fruit and vegetables as well as all field crops. The mission of STÄHLER SUISSE SA covers the development, registration and marketing of plant protection products for professional and non-professional markets. STÄHLER SUISSE SA is an independent Swiss company which equity is held by its management, thus guaranteeing the implementation of a long-term strategy for the business conduct.

Contacts:

Stähler Suisse SA Simon Gasser

Responsable Développement et régistration 41 (0)62 746 80 05 simon.gasser@staehler.ch

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on Euronext Growth. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba

Calyptus

Valérie FILIATRE

Relations investisseurs & Presse

Directeur Général Adjoint

Grégory BOSSON / Mathieu CALLEUX

+33 4 26 69 16 00

+33 1 53 65 37 90 /91

v.filiatre@amoeba-nature.com

amoeba@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the Universal Registration Document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 30, 2020 under number D20-0416 (a copy of which is available on www.amoeba-biocide.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by

Adresse : 38 Avenue des Frères Montgolfier, 69680 CHASSIEU

Tel: +33 (0)4 26 69 16 00 - Email: contact@amoeba-nature.com

Société Anonyme au capital de 311 578,38 €

Linkedin: @amoeba-nature - Twitter: @AmoebaNature

RCS Lyon 523 877 215

www.amoeba-nature.com

AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.

Adresse : 38 Avenue des Frères Montgolfier, 69680 CHASSIEU

Tel: +33 (0)4 26 69 16 00 - Email: contact@amoeba-nature.com

Société Anonyme au capital de 311 578,38 €

Linkedin: @amoeba-nature - Twitter: @AmoebaNature

RCS Lyon 523 877 215

www.amoeba-nature.com

Disclaimer

Amoéba SA published this content on 18 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 December 2020 08:20:01 UTC


© Publicnow 2020
All news about AMOÉBA
02/04AMOEBA : Amoéba announces the issuance of the 11° tranche of bonds convertible i..
PU
01/06AMOEBA : Amoéba announces the issuance of the 10th tranche of bonds convertible ..
PU
2020AMOEBA : Amoéba renews a financing line of up to €23M with Nice & Green to suppo..
PU
2020AMOÉBA : Nomination
CO
2020AMOEBA : Amoéba signs a non-exclusive development and marketing agreement in Swi..
PU
2020AMOEBA : Amoéba announces the appointment of Pierre MORGON as censeur on the Boa..
PU
2020AMOEBA : Amoéba signs an exclusive development and marketing agreement in France..
PU
2020AMOÉBA : Infos Business
CO
2020AMOEBA : Amoéba extends to the USA the testing of its biocontrol products with G..
PU
2020AMOEBA : Amoéba announces the issuance of the 9th tranche of bonds convertible i..
PU
More news
Financials
Sales 2019 0,12 M 0,15 M 0,15 M
Net income 2019 -7,25 M -8,87 M -8,87 M
Net Debt 2019 3,75 M 4,59 M 4,59 M
P/E ratio 2019 -0,57x
Yield 2019 -
Capitalization 41,5 M 50,4 M 50,8 M
EV / Sales 2018 141x
EV / Sales 2019 67,7x
Nbr of Employees 14
Free-Float 97,1%
Chart AMOÉBA
Duration : Period :
Amoéba Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMOÉBA
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Managers and Directors
NameTitle
Fabrice Plasson Chief Executive Officer & Director
Valérie Filiatre Director, Chief Financial & Administrative Officer
Pascal Reber Chairman-Supervisory Board
Jacques Goulpeau Chief Operating Officer
Bernard Ambolet Independent Director
Sector and Competitors